Acute myelogenous leukemia in a patient receiving etanercept for psoriasis

Bachmeyer, Claude; Thiolière, Brigitte; Khosrotehrani, Kiarash; Cattan, E

doi:10.1016/j.jaad.2006.06.032

Cited by 17 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…112 Nair, Raval, and Mehta 113 reported a case of a male patient with psoriasis who was treated with etanercept for 6 months when he developed myelodysplasia with acute myeloid leukemia. Following induction of chemotherapy, the patient developed numerous infectious complications, including septicemia and pneumonia, and his condition deteriorated to the point of his discharge to palliative care.…”

Section: Tnf-a Antagonistsmentioning

confidence: 99%

Treatments for psoriasis and the risk of malignancy

Patel

Clark

Lebwohl³

et al. 2009

Journal of the American Academy of Dermatology

204

147

View full text Add to dashboard Cite

Section: Tnf-a Antagonistsmentioning

confidence: 99%

Treatments for psoriasis and the risk of malignancy

Patel

Clark

Lebwohl³

et al. 2009

Journal of the American Academy of Dermatology

204

147

View full text Add to dashboard Cite

“…7 In the literature, acute leukemia cases due to anti-TNF-a treatment were also reported; however, not as much as lymphoma. [8][9][10][11][12][13][14][15][16] First case was published in 2003. 8 The Food and Drug Administration declared 44 AML cases which developed under the treatment of anti-TNF-a drugs.…”

Section: Discussionmentioning

confidence: 99%

“…9 The relevant case reports about acute leukemia after anti-TNF-a treatment published on MEDLINE are reviewed in Table 1. [10][11][12][13][14][15][16] Ten of the 13 reported patients who developed acute leukemia after anti-TNF-a had AML. AML development may be attributed to higher incidence of this disorder in adults; however, Ph chromosome positivity in all of the three ALL cases is interesting.…”

Section: Discussionmentioning

confidence: 99%

Acute Lymphoid Leukemia After Anti-TNF-alpha Treatment: A Case Report and Review of the Literature

et al. 2015

View full text Add to dashboard Cite

“…61 More recently, Bachmeyer and colleagues documented the development of AML in a man with severe psoriasis also 4 months after etanercept therapy. 62 A third case of AML was reported in a male psoriatic arthritis patient after being treated with etanercept for 6 months. 63 In this report, a chromosome analysis supported the link between biologic therapy and the development of leukemia by revealing a deletion on the chromosome 5p that is consistent with a drug-induced leukemia.…”

Section: Leukemia and Tnf Inhibitorsmentioning

confidence: 99%

Biologic Therapy and the Risk of Malignancy in Psoriasis

Wolinsky

Lebwohl

2011

Psoriasis Forum

View full text Add to dashboard Cite

Biologic agents are currently regarded as a highly efficacious systemic treatment for moderate to severe psoriasis. However, their use in patients with a history of malignancy or an increased risk of cancer is not recommended. The current recommendations are based on several case reports and observational studies, as well as data from randomized, controlled trials, associating these medications with tumorigenic properties. Furthermore, some reports describe malignancies arising de novo in patients using biologic agents. Psoriasis patients are at an increased risk of lymphoproliferative diseases and nonmelanoma skin cancers because of the inflammatory nature of the disease. A blockade of tumor necrosis factor-alpha (TNF-α) reduces inflammation but also may enhance tumor proliferation. Trials have not shown a significant increase in the risk of malignancy, with the exceptions of lymphoma and nonmelanoma skin cancers, with the use of TNF blockers. However, any risk may be unacceptable in a patient with a history or elevated risk of cancer. Ustekinumab acts on a different inflammatory pathway and may have a different profile regarding the risk of malignancy. A comprehensive review of the literature shows some consensus that relative contraindications are active malignancies and malignancies within the past 5 years. There is debate about nonmelanoma skin cancers and melanoma, but it seems prudent to use biologics more cautiously in a patient with a history of aggressive skin cancer, a high risk of recurrent skin cancer, or a history of extreme ultraviolet exposure. Additionally, certain combinations of immunosuppressive therapies, such as purine analogs, with biologics may lead to unacceptable risks of malignancy. Some subgroups, such as patients with chronic obstructive pulmonary disease, are already predisposed to lung cancer because of a significant smoking history; these patients require closer monitoring during biologic therapy. As the biologics are in use longer for psoriasis, more data on the long-term safety of these therapeutics will be available.

show abstract

Acute myelogenous leukemia in a patient receiving etanercept for psoriasis

Cited by 17 publications

References 4 publications

Treatments for psoriasis and the risk of malignancy

Treatments for psoriasis and the risk of malignancy

Acute Lymphoid Leukemia After Anti-TNF-alpha Treatment: A Case Report and Review of the Literature

Biologic Therapy and the Risk of Malignancy in Psoriasis

Contact Info

Product

Resources

About